Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Common Equity (2016 - 2026)

Myriad Genetics has reported Common Equity over the past 16 years, most recently at $368.0 million for Q4 2025.

  • Quarterly Common Equity fell 47.51% to $368.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $368.0 million through Dec 2025, down 47.51% year-over-year, with the annual reading at $368.0 million for FY2025, 47.51% down from the prior year.
  • Common Equity was $368.0 million for Q4 2025 at Myriad Genetics, down from $372.8 million in the prior quarter.
  • Over five years, Common Equity peaked at $968.5 million in Q3 2021 and troughed at $368.0 million in Q4 2025.
  • The 5-year median for Common Equity is $771.6 million (2023), against an average of $760.9 million.
  • Year-over-year, Common Equity increased 9.85% in 2021 and then crashed 49.05% in 2025.
  • A 5-year view of Common Equity shows it stood at $967.8 million in 2021, then decreased by 8.47% to $885.8 million in 2022, then dropped by 11.58% to $783.2 million in 2023, then dropped by 10.48% to $701.1 million in 2024, then crashed by 47.51% to $368.0 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Common Equity are $368.0 million (Q4 2025), $372.8 million (Q3 2025), and $388.1 million (Q2 2025).